Development of clinical trial protocols involving advanced radiation therapy techniques: The European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach

A. Fairchild, R. Bar-Deroma, L. Collette, K. Haustermans, C. Hurkmans, D. Lacombe, P. Maingon, P. Poortmans, M. Tomsej, D. C. Weber, V. Gregoire

Research output: Contribution to journalArticlepeer-review

Abstract

The European Organisation for Research and Treatment of Cancer (EORTC) Master Protocol for phase III radiation therapy (RT) studies was published in 1995 to define in a consistent sequence the parameters which must be addressed when designing a phase III trial 'from the rationale to the references'. This was originally implemented to assist study investigators and writing committees, and to increase homogeneity within Radiation Oncology Group (ROG) study protocols. However, RT planning, delivery, treatment verification and quality assurance (QA) have evolved significantly over the last 15 years and clinical trial protocols must reflect these developments. The goal of this update is to describe the incorporation of these developments into the EORTC-ROG protocol template. Implementation of QA procedures for advanced RT trials is also briefly described as these essential elements must also be clearly articulated. This guide may assist both investigators participating in current ROG trials and others involved in writing an advanced RT trial protocol.

Original languageEnglish
Pages (from-to)1048-1054
Number of pages7
JournalEuropean Journal of Cancer
Volume48
Issue number7
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Clinical trial
  • Intensity-modulated radiation therapy (IMRT)
  • Phase III
  • Protocol
  • Quality assurance
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Development of clinical trial protocols involving advanced radiation therapy techniques: The European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach'. Together they form a unique fingerprint.

Cite this